ישראל - עברית - Ministry of Health

rafa laboratories ltd - morphine sulfate - טבליה - morphine sulfate 15 mg - morphine - morphine - for the relief of moderate to severe pain.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - morphine sulfate - טבליה - morphine sulfate 30 mg - morphine - morphine - for the relief of moderate to severe pain.

ישראל - עברית - Ministry of Health

manon pharm ltd. - ascorbic acid; betacarotene; biotin; calcium carbonate; calcium pantothenate; chromium as chloride; colecalciferol; copper; cyanocobalamin; ferrous fumarate; folic acid; magnesium oxide; manganese as sulfate; nicotinamide; potassium iodide; pyridoxine (vit b6) hydrochloride; riboflavine; sodium molybdate; sodium selenate; thiamine (vit b1) mononitrate; tocopherol (vit e) (as tocopheryl acetate); vitamin a; zinc as oxide - טבליה - betacarotene 1500 iu; vitamin a 1500 iu; ascorbic acid 100 mg; folic acid 1 mg; riboflavine 3.4 mg; nicotinamide 20 mg; cyanocobalamin 12 mcg; colecalciferol 250 iu; biotin 30 mcg; copper 2 mg; sodium molybdate 25 mcg; manganese as sulfate 5 mg; zinc as oxide 25 mg; ferrous fumarate 60 mg; potassium iodide 0.15 mg; magnesium oxide 50 mg; chromium as chloride 25 mcg; calcium pantothenate 10 mg; pyridoxine (vit b6) hydrochloride 10 mg; thiamine (vit b1) mononitrate 3 mg; tocopherol (vit e) (as tocopheryl acetate) 30 iu; calcium carbonate 250 mg; sodium selenate 25 mcg - vitamin and mineral supplement for use during pregnancy and lactation.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin (as sulfate) - קרם - gentamicin (as sulfate) 1 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, combinations with antibiotics - for the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.

ישראל - עברית - Ministry of Health

vetmarket ltd, israel - gentamicin as sulfate; hydrocortisone aceponate; miconazole as nitrate - miconazole as nitrate 15.1 mg/ml; gentamicin as sulfate 1505 iu/ml; hydrocortisone aceponate 1.11 mg/ml

ישראל - עברית - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - קפסולות - larotrectinib as sulfate 100 mg - larotrectinib

ישראל - עברית - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - קפסולות - larotrectinib as sulfate 25 mg - larotrectinib

ישראל - עברית - Ministry of Health

truemed ltd, israel - amikacin as sulfate - תרחיף לשאיפה - amikacin as sulfate 70 mg/ml - amikacin

ישראל - עברית - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or